International Journal of Phonosurgery & Laryngology

Register      Login

VOLUME 1 , ISSUE 2 ( July-December, 2011 ) > List of Articles

RESEARCH ARTICLE

Long-term Follow-up of Patients with Spasmodic Dysphonia Repeatedly Treated with Botulinum Toxin Injections

PH Dejonckere, C Manfredi

Citation Information : Dejonckere P, Manfredi C. Long-term Follow-up of Patients with Spasmodic Dysphonia Repeatedly Treated with Botulinum Toxin Injections. Int J Phonosurg Laryngol 2011; 1 (2):57-60.

DOI: 10.5005/jp-journals-10023-1014

Published Online: 00-12-2011

Copyright Statement:  Copyright © 2011; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Adductor spasmodic dysphonia (SD) is a focal laryngeal dystonia mainly resulting in a strained voice quality with spastic voice breaks and frequency shifts, perturbing fluency and intelligibility. SD-patients report unusually high impairment of their quality of life. The standard treatment is botulinum toxin injection in the thyroarytenoid muscles, in order to interfere with the perturbed sensory feedback loop of kinetic muscle tension regulation. The globally favorable effects are temporary, but the botulinum injections can be repeated. There is a lack of information about long-term effects. This is the first study investigating effects over several years, and comparing self-evaluation of patients with objective multimodal acoustic analysis. Results show that 72% of the individual injections are successful. The effects of botulinum are not reduced after repeated injections. In contrary, the self-perceived improvement increases in average over time. When self-evaluations preinjection are considered, patients tend to evaluate their voice and their handicap as worsening over time. This contrasts with the results of multimodal acoustic analysis. Objective data reveal a relative stability over time for as well pre- as postinjection. This seems to indicate that there is no shift over time in the objective severity of deviance in voice quality.


PDF Share
  1. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: Clinician and patient perception. J Voice 2010;24:242-49.
  2. Perceptual analyses of spasmodic dysphonia before and after treatment. Arch Otolaryngol Head Neck Surg 2004;130:1393-99.
  3. A basic protocol for functional assessment of voice pathology, especially for investigating the efficacy of (phonosurgical) treatments and evaluating new assessments techniques. Guideline elaborated by the Committee on Phoniatrics of the European Laryngological Society (ELS). Eur Arch Otorhinolaryngol 2001;258:77-82.
  4. The voice handicap index (VHI): Development and validation. American J of Speech and Langu Pathol 1997;6:66-70.
  5. Objective evaluation of quality of substitution voices. Eur Arch Otorhinolaryngol 2004;261(10):541-47.
  6. Perceptual evaluation of substitution voices: Development and evaluation of the (I). INFVo rating scale. Eur Arch Otorhinolaryngol 2006;263(2):183-87.
  7. Comparing voice pathologies with the voice handicap inventory: Is a weighting factor required? http://www.siicsalud.com/des/expertos.php/89282, 2008.
  8. Differentiation of adductor-type spasmodic dysphonia from muscle tension dysphonia by spectral analysis. Otolaryngology— Head and Neck Surgery 2007;137:576-81.
  9. Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-Botox injection and within early stages of post-Botox injection. J Speech Language Hearing Res 2002;45:830-43.
  10. Clinical practice guideline: Hoarseness (dysphonia). Otolaryngol Head Neck Surg 2009;141(3 Suppl 2):S1-31.
  11. Spasmodic dysphonia, perceptual and acoustic analysis: Presenting new diagnostic tools. Eur Arch Otorhinolaryngol 2009;266:1915-22.
  12. Pitch and voiced/unvoiced determination with an auditory model. J Acoust Soc Am 1992;91:3511-26.
  13. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): A systematic Cochrane review. Clinical Rehabilitation 2006;20(2):112-22.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.